Physician profile
Anna Wilson
NPI 1326073263
$3,986.78
in general payments reported to CMS, 2019-2025
21 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $612 · 2023: $1,063 · 2024: $836 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,375.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,114.02 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $916.92 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $505.31 | 2023-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.42 | 2022-2025 | Ofev, Spiriva Respimat, Jascayd |
| Lilly USA, LLC | $205.63 | 2024-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.11 | 2025 | Caplyta |
| Abiomed | $137.14 | 2024 | Impella |
| Mylan Specialty L.P. | $110.53 | 2022-2024 | Yupelri |
| Intra-Sana Laboratories | $79.32 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Genzyme Corporation | $38.90 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $37.83 | 2025 | Dupixent |
| Sumitomo Pharma America, INC. | $31.28 | 2023 | Gemtesa |
| Urovant Sciences INC | $29.80 | 2022 | |
| Exact Sciences Corporation | $24.51 | 2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $22.80 | 2025 | Hetlioz, Fanapt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.49 | 2025 | Rexulti |
| Grifols USA, LLC | $20.86 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.84 | 2025 | Uptravi |
| Dexcom, INC. | $15.48 | 2024 | Dexcom G6 Transmitter |
| Solta Medical, A Division of Bausch Health US, LLC | $15.25 | 2025 | Clear+Brilliant |
| Insmed, INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.